Navigation Links
New treatment using inhaled interferon may improve lung function in pulmonary fibrosis
Date:2/29/2012

New Rochelle -- Inhaled interferon-gamma may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a chronic and progressive form of lung disease caused by excessive formation of fibrotic, or scar tissue, in the lungs, according to an article published in Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp), a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article on inhaled interferon-gamma (http://online.liebertpub.com/doi/abs/10.1089/jamp.2011.0919) is available free online at the Journal of Aerosol Medicine and Pulmonary Drug Delivery website.

Normally, systemic delivery of interferon-gamma can cause substantial side effects; however, delivery of aerosolized interferon-gamma directly into the lungs was shown to be safe and was associated with significantly reduced levels of profibrotic regulatory proteins. Keith Diaz, MD, Shibu Skaria, MD, Keith Harris, MD, Mario Solomita, DO, Stephanie Lau, MD, Kristy Bauer, MD, Gerald Smaldone, MD, PhD, and Rany Condos, MD, State University of New York, Stony Brook and New York University School of Medicine, NYC, show that inhalation of interferon-gamma in aerosol form three times a week for at least 80 weeks was well-tolerated by patients, with no systemic side effects.

The authors verified the presence of the drug in the material collected on lung washes and documented no change in the level of interferon-gamma in the blood during the treatment period. The report shows the results of pulmonary function tests, including forced vital capacity (FVC) and total lung capacity (TLC), and the effects of treatment on a six-minute walk test in the article entitled "Delivery and Safety of Inhaled Interferon-gamma in Idiopathic Pulmonary Fibrosis." (http://online.liebertpub.com/doi/abs/10.1089/jamp.2011.0919)

"There is no treatment for Idiopathic Pulmonary Fibrosis, a disease usually fatal within 3-5 years," says Gerald C. Smaldone, MD, PhD, Editor-in-Chief of the Journal and a coauthor of this article, and Professor and Chief, Division of Pulmonary and Critical Care Medicine at SUNY-Stony Brook. "The scientific community expected the injected form of interferon-gamma to help, but those studies failed. We have shown that inhaled interferon is safe with very high levels in the lungs. Now is the time to repeat the clinical trials with the inhaled form of this therapy."


'/>"/>
Contact: Cathia Falvey
cfalvey@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. The dietary supplement genistein can undermine breast cancer treatment
3. Coming soon: Self-guided, computer-based depression treatment
4. Nanodiamond drug device could transform cancer treatment
5. Disinfectants can make bacteria resistant to treatment
6. Scientists from Granada find a potential treatment to prevent diabetes and obesity
7. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
8. Researchers at National Jewish Health evaluating a treatment
9. National Jewish Health researchers evaluating treatment to help emphysema sufferers breathe easier
10. First comprehensive genomic study of common cold reveals new treatment targets
11. Iowa State researcher develops new treatment method for canine eye diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New treatment using inhaled interferon may improve lung function in pulmonary fibrosis
(Date:3/13/2017)... -- Future of security: Biometric Face Matching software  ... ... Face Matching enables to match face pictures against each other or against large ... Identification Systems) ... is the fastest software for biometric Face Matching on the market. The speed ...
(Date:3/7/2017)... 2017   HireVue , the leading provider of ... the best talent, faster, today announced the additions of ... and Diana Kucer as Chief Marketing Officer ... team poised to drive continued growth in the company,s ... of record bookings in 2017. "Companies worldwide ...
(Date:3/2/2017)... , March 2, 2017 Who risk ... lawsuits? Download the full report: https://www.reportbuyer.com/product/4313699/ ... THE FINGERPRINT SENSOR FIELD? Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
Breaking Biology News(10 mins):
(Date:3/30/2017)... ... March 30, 2017 , ... Accelovance, Inc., a ... announced the hiring of Bruce Wakeman into the role of VP US Business ... President, Proposals & Marketing. , Bruce brings Accelovance over 20 years’ experience in ...
(Date:3/30/2017)... ... 30, 2017 , ... DrugDev will join Boston’s ... NewCo festival on April 5. NewCo invites participants to the offices of inspiring ... , DrugDev – operating at the intersection of innovative healthcare and cutting-edge technology ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... attention to Agenus Inc. (NASDAQ: AGEN), Intrexon Corp. (NYSE: ... Corp. (NASDAQ: CXRX ). According an article ... sector to "Overweight" from "Market Weight" on Tuesday, March 21 st ... by simply registering for free at: ...
(Date:3/29/2017)... ... March 29, 2017 , ... Zansors announced today its ... issued by the U.S. Patent & Trademark Office (USPTO). The patent covers a ... health monitoring. This invention will be critical to the future of wearable tech ...
Breaking Biology Technology: